A G E N D A 1. APOLOGIES FOR ABSENCE Ian Metcalfe 2 ...

Full details of the QIAs for the clinical schemes is shown in Appendix A. A summary is providedbelow:DirectorateNo ofSchemesSchemes not approved by MedicalDirector and Director of Nursing atfirst reviewAnaesthetics 9 0Trauma and Orthopaedics 12 0Specialist Services 14 0Surgical Specialties 17 0Cardiology 5 0Acute Surgery 16 0PPT 28 PPT006, PPT011, PPT028 3Medicine 6 MED006 1Radiology 13 0Maternity 10 MAT008, MAT015 2Cancer Care 15 CA005, CA020, CA021, CA027, CA030 5Total 145 11Not signed offOngoing Monitoring of QIAsThe following process has been agreed at PMG:• Directorates will review current QIAs and clarify the specific metrics that will be used forongoing monitoring of performance and impact• Directorate will set KPI base lines for identified metrics in order to monitor variance in year andquantify positive or negative impact• Schemes will be monitored at Directorate Team meetings – or other relevant forums• Directorate will formally record status in monthly TMB reporting – TMB template to be amendedto enable reporting by exception• CIPs and QIAs to be reviewed exception at PMG• System for providing independent scrutiny to be devised• Directorate to raise to risk level at CGRC and HAC as appropriateRecommendationHAC agreed to support the QIA process for 2013/14 and recommends this to the Board of Directors